STAT Plus: Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results
Alzheimer’s
Alzheimer’s research news: Here’s the latest on Alzheimer’s disease, from research and development to policy debates on new drugs and treatments. Alzheimer’s, the most common cause of dementia, is the sixth leading cause of death in the U.S.
Latest
Taxi drivers are steering neuroscience toward better understanding Alzheimer’s
STAT Plus: Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
STAT Plus: Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
STAT Plus: Mild Alzheimer’s patients won’t save Cassava Sciences
STAT Plus: Small mid-stage trial suggests targeted magnetic pulses to brain could slow Alzheimer’s
Congressional races to watch, auditory hallucinations, Alzheimer’s drug data
STAT Plus: Eli Lilly says modified dosing of its Alzheimer’s drug may be safer
All Coverage
advertisement
